All AbMole products are for research use only, cannot be used for human consumption.
TRAM-34 is a selective and potent inhibitor of the intermediate-conductance Ca2+-activated K+ channel (IKCa1, KCa3.1) with Kd of 20 nM. Unlike clotrimazole, TRAM-34 dose not inhibit mammalian cytochrome P450 enzyme (CYP3A4). TRAM-34 displays >200-fold selectivity for IKCa1 over Kv, BKCa, SKCa, Na, CRAC, and chloride channels. TRAM-34 does not exhibit toxicity against a variety of cell lines in vitro or cause obvious deleterious changes in a limited short-term acute toxicity study in rodents. TRAM-34 significantly inhibits the reactivation process of human lymphocytes by mitogenic stimuli, and when in combination with cyclosporin A suppresses T-cell mitogenesis more potently than either compound alone. TRAM-34 significantly inhibits EGF-induced IKCa1 up-regulation, and EGF-stimulated proliferation of A7r5 cells. TRAM-34 treatment at 120 mg/kg/day significantly reduces intimal hyperplasia in rat model of balloon catheter injury (BCI). TRAM-34 inhibits human endometrial cancer (EC) cell proliferation, arrests its cell cycle at G0/G1 phase, and suppresses the development of EC tumors in nude mice. By specifically targeting IKCa1, TRAM-34 treatment inhibits the prostate cancer (PCa) cell proliferation in a dose-dependent manner, involving growth arrest and an accumulation of p21Cip1.
| Cell Experiment | |
|---|---|
| Cell lines | Human T lymphocytes, Jurkat E6-1, MEL, C2F3, CHO, COS-7, L929, NGP, NLF, and RBL-2H3 |
| Preparation method | Exposing cells to TRAM-34 for 48 hours. 48 hours later , cells are harvested by suction (suspension cells) or by trypsinization (adherent cell lines), centrifuged, resuspended in 0.5 mL PBS containing 1 μg/mL propidium iodide (PI), and measured red fluorescence on a FACScan flow cytometer. The percentage of dead cells is determined by their PI uptake, 104 cells of every sample being analyzed. |
| Concentrations | Dissolved in DMSO, final concentration ~10 μM |
| Incubation time | 48 hours |
| Animal Experiment | |
|---|---|
| Animal models | Sprague-Dawley rats subjected to BCI of the left CA by use of a 2F Fogarty embolectomy catheter |
| Formulation | Formulated in peanut oil |
| Dosages | 120 mg/kg/day |
| Administration | Subcutaneous injection |
| Molecular Weight | 344.84 |
| Formula | C22H17ClN2 |
| CAS Number | 289905-88-0 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[5] Tom Schilling, et al. TRAM-34 inhibits nonselective cation channels
| Related Potassium Channel Products |
|---|
| VU0810464
VU0810464 is a potent and selective non-ureaG protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) activator. VU0810464 displays nanomolar potency for neuronal (EC50=165 nM) and GIRK1/4 (EC50=720 nM) channels with improved brain penetration. |
| QO 58
QO 58 is a potent modulator of K(v)7 channels. |
| NS3623
NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. |
| ML67-33
ML67-33 is a selective activator of temperature- and mechano-sensitive K2P channels. |
| A-935142
A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
